Anti-PAI-1 (human, plasminogen activator inhibitor type I)
Mouse monoclonal antibody
Cat.No. MON I-5
Preparation: Protein-G purified
Content: Available in 200 µL and 1 mL
Concentration: 1 mg/mL
Solvent: 0.01 M phosphate buffer, pH 7.4, with 0.5 M NaCl and 15 mM sodium azide
Storage: In the dark at 4-8ºC
Plasminogen activator inhibitor-1 (PAI-1) is the principal inhibitor of urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA). It belongs to the group of serpins (serine protease inhibitors). Elevated levels of PAI-1 are associated with poor prognosis in many types of cancer (1-5).
Native PAI-1
MON I-5 is specific for human PAI-1. No cross-reactivity is observed with PAI-2 as tested by ELISA and immunoblotting. No reactivity is observed with any other human plasma protein when tested by immunoblotting.
MON I-5 binds to an epitope consisting of amino acids 284-294 (6)
MON I-5 reacts with PAI-1 as tested by ELISA and immunoblotting and can be used as coating antibody for uPA:PAI-1 ELISA (7). For immunohistochemistry applications MON I-5 can be used on frozen sections.
| Method | Usability | Dilution guideline | References |
| ELISA | Yes | 7 | |
| Immunoblotting | Yes | ||
| Immunohistochemistry | Yes |
1. Andreasen PA (2007) PAI-1 - a potential therapeutic target in cancer. Current Drug Target 9:1030-1041
2. Loskutoff DJ, Curriden SA, Hu G, Deng G (1999) Regulation of adhesion by PAI-1. APMIS 107:54-61.
3. Andreasen PA, Kjøller L, Christensen (1997) The urokinase plasminogen activator system in cancer metastasis. A review. Int J Cancer 2:1-22.
4. Harbeck N, Kates RE, Look MP (2002) Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk acording to urokinase -type plasminogen activator and plasminogen activator inhibitor type 1 (n=3424). Cancer Res 62:4617-22.
5. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513-2521.
6. Munch M, Heegaard C, Jensen PH, Andreasen PA (1991) Type-1 inhibitor of plasminogen activators. Distincton between latent, activated and reactive centre-cleaved forms with thermal stability and monoclonal antibodies. FEBS Lett 295: 102-106.
7. Pedersen AN, Høyer-Hansen G, Brünner N, Clark GM, Larsen B, Poulsen HS, Danø K, Stephens RW (1997) The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA. J Imm Meth 203:55-65.
Related Articles
Antibody MSDS
April 23 2008
Related News
New tools for cancer research: Plasminogen Activation System anti-bodies
May 05 2008
